Key result
Direct oral anticoagulants resulted in a similar rate of recurrent venous thromboembolism compared to traditional anticoagulants in morbidly obese patients (2.96% vs 2.54%; OR 1.17).
Why the study?
Smaller studies have compared DOACs with warfarin or LMWH in morbidly obese patients with VTE, but a systematic review and meta-analysis of direct comparative data was needed.
Do direct oral anticoagulants prevent recurrent VTE and major bleeding with similar efficacy and safety to traditional anticoagulants in morbidly obese patients with acute VTE?
Systematic Review (n=6,575)
Do direct oral anticoagulants prevent recurrent VTE and major bleeding with similar efficacy and safety to traditional anticoagulants in morbidly obese patients with acute VTE?
Odds Ratio: 1.17 (95% CI 0.87–1.59)
Absolute Event Rate: 2.96% vs 2.54%
p-value: p=0.30
DOACs demonstrated similar efficacy and safety compared to traditional anticoagulants for the treatment of acute VTE in morbidly obese patients.
No takes yet. Share an insight, caveat, or question.
Supports DOAC use in morbidly obese VTE patients; extends evidence to this subgroup.
Katel et al. (2021) conducted a systematic review in Acute venous thromboembolism in morbidly obese patients (n=6,575). Direct oral anticoagulants vs. Vitamin K antagonists or low molecular weight heparin was evaluated on Recurrent venous thromboembolism (OR 1.17, 95% CI 0.87-1.59, p=0.30). Direct oral anticoagulants resulted in a similar rate of recurrent venous thromboembolism compared to traditional anticoagulants in morbidly obese patients (2.96% vs 2.54%; OR 1.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: